

## **Consent Agenda (Nov. 8, 2021 Board Meeting)**

### **ICR Governing Board Meeting**

**October 8, 2021 12:00 – 1:00 pm**

**Meeting By Zoom:** <https://csupueblo.zoom.us/j/95780770453>

**In attendance: Dr. Cinnamon Bidwell, Dr. Malik Hasan, Dr. Chad Kinney, Mr. Ean Seeb, Dr. Joanna Zeiger, Dr. Jon Reuter, Mr. Tyler Mounsey, Mr. Sal Pace, Dr. Tim Mottet, Mr. Skip Spear, Ms. Elyse Contreras, MPH, Dr. Sue Sisley, and Ms. Wendy Fairchild**

### **Meeting Minutes:**

- I. Welcome (12:00-12:03pm) Dr. Bidwell
- II. Consent Agenda (12:03-12:08pm) Dr. Bidwell
  - a. Minutes from 09/10/2021
  - b. Emerging Scientist Award
  - c. Revised Strategic Goals for the ICR Website
    - Dr. Bidwell suggested motion to approve the consent agenda – Dr. Mottet so moved, Dr. Jon Reuter seconded and Dr. Sue Sisley, Mr. Sal Pace, Dr. Joanna Zeiger and Dr. Malik Hasan voted yes
    - No votes against
- III. Introduce New Gov. Board Member – Dr. Joanna Zeiger (12:08-12:13pm) Dr. Bidwell
  - Cannabis epidemiologist, studied at John Hopkins, former triathlete
- IV. ICR Gov. Board – CSU Pueblo MOU – Discussion and Approval (12:13-12:23pm) Dr. Bidwell
  - Mr. Skip Spears – took 18 months to get here
  - Dr. Mottet has question on page 7 regarding 10% fee
  - Dr. Hasan says “too high” – wishes to register his dissent
  - Dr. Bidwell says low rate, fairly conservative, been a part of the of the ICR budget since before the Board was formed
  - Mr. Spears says this is more than rent and Dr. Bidwell mentions HR, IT, personnel, and etc. are part of cost
  - Dr. Mottet offered to itemize the services and will share with Dr. Hasan
  - Mr. Pace can see this is within ballpark – concern is the percentage
  - Dr. Kinney explained the rate was negotiated with the state prior to his tenure with the ICR.
  - Dr. Zeigler suggests a cap on amount of money (used over \$500,000 as an example)
  - Mr. Spear had to depart the meeting at 12:25pm
  - Dr. Hasan asks that we place the topic on hold as uncomfortable with the \$170,000 amount
  - Dr. Bidwell will move forward with providing more information to Dr. Hasan
  - Ms. Contreras discussed her experience with CDPHE fees and contracts that paid for personnel, contract monitoring, space, and etc.

- Dr. Bidwell will provide more information and asks that other questions be sent to her
- V. Mr. Tyler Mounsey – Gov. Rel. Rep. (12:13-12:40pm) Dr. Bidwell
- a. Introduction
    - Government relations representative Selected to represent the ICR (awaiting contract execution) – from New York, now a Coloradoan – moved from politics to public relations – until recently , worked on campaigns for president, governors, representatives, and etc. – manages many types of personalities – will be megaphone for the ICR fact based approach and will over-communicate clearly and often
    - Dr. Kinney asked how the Board can assist/support his future work.
    - Mr. Mounsey says the Board members are the experts – he appreciates the “big brain trust” here, and wants to encourage over communication – Board is invaluable for getting people to work together to testify, write letters and communicate directly
  - b. Initial Goals
    - i. Interim
    - ii. Session
  - c. Reporting
  - d. Invitation for individual meetings
- VI. Request for Applications (RFA) (12:40-12:55) Dr. Kinney
- a. Setting up an RFA for funding to start next FY
    - Ready to jump in in regard to research applications – (shared screen) – says attempting to be prepared when sending out RFA
  - b. Timeline (delayed a couple of months compared to last FY)
    - would like to announce early next calendar year – use language as dependent upon available funding - announce RFA, guidelines for applying, LOI - areas of expertise can be determined from this – several months then full applications
  - c. Proposed Budget
  - d. Research Priorities – Survey (Results Next Month)
    - Research Sub-Committee – 3 categories - good approach with some emphasis areas/priorities
    - \$1.6 million into new research projects – ranges not set in stone just illustration (possible distribution)
    - There would be 6-8 new projects with this scenario
    - F&A kept low, rate of 15% - good stewards of State research money
    - Second level review (Gov Board) – important to protect against duplication of previously funded research. This will not be done as part of the panel review. Panel will focus on merits of the projects.
    - Dr. Bidwell – information will be brought forward for input a few times more before finalized
    - Dr. Zeiger – might be helpful to have list of projects already awarded- Investigator can get glimpse of what the ICR is doing and what award looks like
    - Dr. Reuter – lots of tiers to manage – fund best quality grants – re-appropriate funds if something more realistic meets our needs

- Dr. Bidwell – agrees with this notion – suggests we want researchers to know about higher limits and potential range of budgetary options for projects – addressed question about “carry-overs”- says this is not new problem but can navigate as before – careful consideration as in past

VII. Public Comment (12:55-1:00pm) Dr. Bidwell

- Dr. William Silvers – Happy ICR is moving forward – lots of kudos and continue forth
- Dr. Bidwell will follow up with Dr. Mottet and put together a plan to move forward with MOU
- Mr. Seeb thanks Dr. Silvers for his ongoing support – knows Tyler Mounsey personally and says he appreciates his morals, ethics, transparency and experience with State Government – thanks Drs. Bidwell and Kinney as well as Mr. Pace for work with Governing Board – small incremental steps to get where we are – delighted by progression – Governor is delighted
- Dr. Bidwell – says gratitude goes both ways

VIII. Adjourn

- 1:00pm

## **ICR Emerging Scientist Award Updates**

**Applications:** 7 were received

**Projects Represented:** 7 of the 10 research teams are represented in the applications

**Institutions Represented:** 4 institutions of higher education represented

**Total Request:** \$35,000

**Review:** Week of Nov 8<sup>th</sup>





# Institute of Cannabis Research

COLORADO STATE UNIVERSITY PUEBLO

In 2016 Colorado and Pueblo County had the forethought to provide the resources that led to the creation of the Institute of Cannabis Research (ICR) at Colorado State University Pueblo. The ICR became the nation's first multi-disciplinary cannabis research center at a regional, comprehensive institution. Primary functions of the ICR are to facilitate cannabis research and the dissemination of research results.

## The ICR:

- Supports Cannabis Research in Colorado
- Hosts the annual Cannabis Research Conference
- Sponsors the publication of the *Journal of Cannabis Research*
- Hosts a monthly Cannabis Research Webinar Series

**Research:** The ICR conducted its first statewide competition for research support that was modeled after the award process from the National Institute of Health (NIH). and 10 meritorious proposals were awarded funding at a range of Colorado Institutions including: *CU Boulder, CU Anschutz, CSU Fort Collins, CSU Pueblo, and MX, LLC.* The projects will continue to grow our knowledge of cannabis. Below please find a summary of most of these projects:

(for a complete list of projects and descriptions visit the ICR's [Website](#))



**Dr. Emily Bates: (CBD and Pregnancy)** Morning sickness during pregnancy can be debilitating for a significant portion of women. Because there are not good remedies easily available and marijuana can help with nausea, women are drawn to using it, or the non-psychoactive component cannabidiol (CBD), thinking it is safe for their unborn child. Results from this project will allow us to learn how fetal exposure to CBD affects brain development and anxiety behaviors.



**Dr. Cinnamon Bidwell and Dr. Tyrell Towle: (Cannabis Products and Label Accuracy)** The goal of this project is to determine the actual cannabinoid content of cannabis products found in the Colorado Retail Cannabis marketplace) and compare to the stated cannabinoid content found on the product label. Over 450 authentic cannabis products from four basic categories: flower/joints, edible/ingestible, concentrate, and other/infused will be randomly selected, purchased from state-licensed retail dispensaries, and tested.



**Dr. Ashley Brooks-Russell: (Acute Cannabis Use and Driving)** Police officers have long recognized that changes to the eyes, such as changes to the pupils or eye movements, can be a sign of recent drug use. Eye-scanning technology will be assessed as a potential tool to detect impairment related to cannabis while driving a vehicle or in an occupational setting. Results from this study will be beneficial to law enforcement, legal experts and other public health regulators.



**Dr. Hollis Karoly: (Impacts of Combined Alcohol and Cannabis Use)** Cannabis is the most commonly used drug among people who drink alcohol, yet an understanding of the effects of using these substances together is quite limited. Two important considerations that might impact the impacts of cannabis and alcohol use are the specific type of cannabis used (i.e., THC/CBD content and potency) as well as the order of use (i.e., using alcohol before cannabis or cannabis before alcohol). Research from this project will be beneficial to the cannabis consuming public, regulators, legislators and other public health officials.





**Dr. Stephanie McGrath: (Potential CBD Efficacy for Alzheimer's Disease)** Alzheimer's disease (AD) and other dementias are expected to be the second leading cause of death in the United States within the next decade. Canine cognitive dysfunction syndrome (CCD) is a well-recognized neurodegenerative disease that serves as an ideal naturally occurring surrogate for AD in humans. Promising data have revealed that cannabidiol (CBD) and trazodone may have beneficial effects on various phases of the neurodegenerative process, which will be tested alone and in combination, as a preventive and therapeutic option in dogs, acting as a translational model for use in humans. The results of this in vivo study will set the foundation for human clinical trials.



**Dr. Ken Olejar: (CBD and CBN Production and Increased Bioavailability)** Large numbers of therapeutics originate from compounds in plants. Cannabinoids produced by cannabis have garnered interest for potential medical use. This project will focus on the efficient production of the cannabinoid CBD and CBN (produced from CBD) along with analogues of these cannabinoids that will be tested for efficacy against a Rheumatoid arthritis model and in breast cancer. Research from this project may inform the future production and development of therapeutic applications of cannabinoids and their analogues.



**Dr. Nichole Reisdorph: (Effects of Cannabis on Neurotransmitters and Anxiety)** Orally consumed Cannabis and extracted cannabidiol (CBD) products are increasingly used supplements for a range of health disorders, including depression and anxiety. This research will help determine the role of gut microbiome in how Cannabis derived molecules are metabolize. Results can be used to design similar studies focused on other disorders such as post-traumatic stress disorder (PTSD). This research study will be beneficial to the health community including veteran's services, psychiatric community as well as other public health regulators.



**Dr. Camille Stewart (Cannabinoids use for Pain Management Following Surgery for Cancer)** Interest in Cannabis and its derivatives for pain management is growing, yet there is a critical lacking of understanding of how cannabis and its derivatives affect patients after surgery. Cannabis is of interest to surgical patients diagnosed with cancer, and therefore they represent an ideal population to study. Blood cannabinoid levels, pain levels, pain medication requirements, and post-surgery complications will be assessed in daily cannabis users and non-users undergoing surgery for cancer. This research will help doctors and patients understand how cannabis use affects surgical patients and help determine if cannabis use is safe around the time of surgery.

**Moving Forward:** To meet the mission the state has set forth the ICR requires the Institute engage talented researchers throughout Colorado to engage in a diverse cross section of cannabis research. Research is needed to address the many questions surrounding cannabis in a changing regulatory and policy landscape as well as address potential applications of cannabis. Cannabis research cannot be stagnant or be of secondary importance if public health and advanced applications are a priority.